# Eli Lilly’s Tirzepatide Removed from Shortage List – Compounders are suing the FDA after Eli Lilly’s tirzepatide was removed from the drug shortage list. – The compounders argue that removing tirzepatide from the list would limit patient access to the drug. – Eli Lilly has stated that they are working to increase the supply of tirzepatide to meet the demand. ### Compounders vs. FDA Compounders are taking legal action against the U.S. Food and Drug Administration (FDA) for their decision to remove Eli Lilly’s tirzepatide from the drug shortage list. The move to remove the drug from the list has sparked controversy, with compounders arguing that this decision will have a negative impact on patient access to the medication. ### Eli Lilly’s Response Eli Lilly, the pharmaceutical company behind tirzepatide, has reassured patients and healthcare providers that they are actively working to ramp up the production of the drug. They are committed to ensuring that there is an adequate supply of tirzepatide to meet the needs of patients who rely on this medication for their health and well-being. ### Legal Battle As the compounders challenge the FDA’s decision in court, the outcome of this legal battle remains uncertain. Patients and healthcare professionals are encouraged to stay informed about the situation and work closely with their healthcare providers to explore alternative treatment options if needed. **Hot Take:** Ensuring access to essential medications like tirzepatide is crucial for patients managing their health. If you are looking for support and guidance on your weight loss journey, reach out to Mindful Evolution at https://yourmindfulevolution.com or call/text us at 954-639-9960. *Weight Loss Disclaimer: Individual results may vary. Mindful Evolution offers telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.*